Continuation of proton pump inhibitors from hospital to community

被引:54
作者
Grant, Kenneth
Al-Adhami, Noor
Tordoff, June [1 ]
Livesey, Jocelyn
Barbezat, Gil
Reith, David
机构
[1] Univ Otago, Sch Pharm, Dunedin, New Zealand
[2] Dunedin Publ Hosp, Dept Pharm, Dunedin, New Zealand
[3] Univ Otago, Dunedin Sch Med, Dunedin, New Zealand
来源
PHARMACY WORLD & SCIENCE | 2006年 / 28卷 / 04期
关键词
drug use study; hospital discharge; hospital prescribing; New Zealand; proton pump inhibitors;
D O I
10.1007/s11096-006-9028-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objectives To evaluate the appropriateness of initiation of proton pump inhibitor (PPI) treatment in hospital, the quality of discharge information, and any association with continued treatment in the community. Methods Survey of all inpatients newly initiated on a PPI in June-August 2003. Assessment of appropriateness of therapy and completeness of discharge information; assessment of continuation of PPI therapy in the community after 6 months. Results Thirty-five of 58 patients (60%) were considered appropriately commenced on PPI treatment. Less than 25% of patients discharged on a PPI had discharge information recommending duration of treatment or review. In the "appropriate" group 30 patients (86%) were discharged on omeprazole, and 13/21 (62%) evaluable patients remained on this at 6 months. In the "inappropriate" group 15 (65%) were discharged on omeprazole, and 10/14 (71%) evaluable patients remained on this at 6 months. Older patients remained on omeprazole for a longer duration but appropriateness of commencement did not influence the duration of treatment. Dose titration was attempted for 10 (29%) patients including three from the "inappropriate" group. Conclusion Care should be taken to commence PPIs only when clinically indicated. Discharge information to GPs, especially recommendations for duration of treatment and/or dose titration, requires improvement.
引用
收藏
页码:189 / 193
页数:5
相关论文
共 10 条
  • [1] *AUSTR DEP HLTH AG, 2004, PHARM BEN SCHEM
  • [2] CHURCH N, 2002, EVIDENCE BASED GASTR, P118
  • [3] An evidence-based appraisal of reflux disease management - the Genval workshop report
    Dent, J
    Brun, J
    Fendrick, AM
    Fennerty, MB
    Janssens, J
    Kahrilas, PJ
    Lauritsen, K
    Reynolds, JC
    Shaw, M
    Talley, NJ
    [J]. GUT, 1999, 44 : S1 - S16
  • [4] *DEP HLTH, 2005, PRESCR COST AN ENGL
  • [5] *NZ GUID GROUP, 2004, MAN DYSP HEARTB, P1
  • [6] *PHARM MAN AG, 2004, ANN REV 2004
  • [7] Concordance between use of proton pump inhibitors and prescribing guidelines
    Pillans, PI
    Kubler, PA
    Radford, JM
    Overland, V
    [J]. MEDICAL JOURNAL OF AUSTRALIA, 2000, 172 (01) : 16 - 18
  • [8] Proton pump inhibitors: update on their role in acid-related gastrointestinal diseases
    Robinson, M
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2005, 59 (06) : 709 - 715
  • [9] Stowasser Danielle A., 1997, Australian Journal of Hospital Pharmacy, V27, P362
  • [10] VANWALRAVEN C, 1995, CAN MED ASSOC J, V152, P1437